Clinical trial will compare cannabis with fentanyl for rapid-onset cancer pain

Approximately 60 patients suffering breakthrough cancer pain will participate in a clinical trial that compares fentanyl medication with an inhaled medical cannabis product developed by Tetra Bio-Pharma.

Rapid-onset opioids are the standard treatment for breakthrough cancer pain, which comes on quickly and is extremely intense.

Tetra Bio-Pharma said clinical data already shows that its lead drug, PPP001, can bring rapid relief and may even be a faster-acting alternative to opioid fentanyl.

Led by McGill University professor Antonio Vigano, MD, and in collaboration with Sante Cannabis, the study is expected to start in December, with recruitment to follow.

As a prescription drug with a Drug Identification Number, Tetra’s cannabis-based medication will be eligible for insurance coverage and be accessible in pharmacies.

 

 

 

2 thoughts on “Clinical trial will compare cannabis with fentanyl for rapid-onset cancer pain

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s